Prosecution Insights
Last updated: November 20, 2026

Mark V Stevens, USPTO Patent Examiner

Listed by the USPTO as STEVENS, MARK V

Tech Center 1600 • Art Units: 1600 1613 1646 1655

This examiner grants 66% of resolved cases

Analysis

STEVENS, MARK V is assigned to technology center 1600 and art unit 1600. The profile reports 881 resolved cases, an allowance rate of 65.5%, and an interview lift of 41.4%. The median time to allowance is 977 days. The extensive case record supports meaningful historical analysis, and the interview measure provides a substantial additional factor for planning prosecution communications.

The listed companies are Antecip Bioventures Ii LLC, The Regents of the University of Michigan, and The Procter & Gamble Company. The listed firms are HESLIN ROTHENBERG FARLEY & MESITI PC, BIRCH STEWART KOLASCH & BIRCH, LLP, and Casimir Jones, S.C. Counsel can combine these stakeholder patterns with the outcome and timing data when developing matter-specific strategy.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

65.5%
Allow Rate
+5.5% vs TC avg
951
Total Applications
+41.4%
Interview Lift
977
Avg Prosecution Days
Based on 881 resolved cases, 2023–2026

Rejection Statute Breakdown

5.1%
§101 Eligibility
11.7%
§102 Novelty
39.8%
§103 Obviousness
23.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18911341 ORAL CARE COMPOSITIONS COMPRISING DICARBOXYLIC ACID Non-Final OA The Procter & Gamble Company
17694270 DELIVERY OF SURFACTANT SOLUBLE ANTI-DANDRUFF AGENT Non-Final OA The Procter & Gamble Company
18293204 POLYMER NANOPARTICLES VIA CONDENSED DROPLET POLYMERIZATION Final Rejection CORNELL UNIVERSITY
18570690 BIOMATERIALS COATING FOR ON-DEMAND BACTERIA DELIVERY AND METHOD TO TREAT COLITIS AND IRRITABLE BOWEL SYNDROME Final Rejection Wisconsin Alumni Research Foundation
18169695 HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING Final Rejection The General Hospital Corporation
19110125 USE OF AN ALKYLETHER SULFATE FOR IMPROVING THE EFFICACY OF HERBICIDES Non-Final OA BASF SE
18838825 MODIFIED RELEASE VALPROIC ACID SOFTGEL CAPSULE Final Rejection R.P. SCHERER TECHNOLOGIES, LLC
18880365 COMPOSITION FOR INDUCING LIGAMENTIZATION OF TENDON, COMPRISING ANTERIOR CRUCIATE LIGAMENT-DERIVED STEM CELLS Non-Final OA IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
18738288 Zinc Phosphate Complex Final Rejection Colgate-Palmolive Company
19104001 SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES FOR IMMUNOTHERAPY Non-Final OA BRAIN & BEYONDS CO., LTD.
18847701 HAIR CONDITIONER FORMULATION Non-Final OA Dow Silicones Corporation
18851376 Stable Dentrifice Compositions With High Sodium Bicarbonate Loading Non-Final OA Lubrizol Advanced Materials, Inc.
18747164 MICROWAVE ASSISTED EXTRACTION OF ESSENTIAL OILS FROM PLANT BIOMASS Final Rejection Firmenich SA
18778471 POLYMERSOME NANOPARTICLES EXHAUSTING INTRACELLUAR AMINO ACID FOR CANCER THERAPY AND METHODS THEREOF Final Rejection THE UNIVERSITY OF HONG KONG
18198471 Multivitamin Non-Final OA Individual inventor

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Mark V Stevens's allowance rate?

65.5% of resolved applications examined by Mark V Stevens were allowed (881 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.

Does an interview help with examiner Mark V Stevens?

This examiner's interview lift is +41.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Mark V Stevens take to allow a patent?

Applications allowed by Mark V Stevens took 977 days on average from filing to allowance.

Which art unit does examiner Mark V Stevens work in?

Mark V Stevens examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month